Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762581 | 0.89 | OPRK1 (1.00) | OPRK1OPRM1 | |
| SCHEMBL21090032 | 0.89 | OPRK1 (0.79) | OPRK1OPRM1 | |
| SCHEMBL21090020 | 0.89 | OPRK1 (0.79) | OPRK1OPRM1 | |
| SCHEMBL21090036 | 0.89 | OPRK1 (0.79) | OPRK1OPRM1 | |
| SCHEMBL23494611 | 0.89 | OPRK1 (0.79) | OPRK1OPRM1 | |
| SCHEMBL23515446 | 0.89 | OPRK1 (0.79) | OPRK1OPRM1 | |
| SCHEMBL21090035 | 0.89 | OPRK1 (0.79) | OPRK1OPRM1 | |
| SCHEMBL3765437 | 0.88 | OPRK1 (1.00) | OPRK1OPRM1 | |
| SCHEMBL16237575 | 0.88 | OPRK1 (0.82) | OPRK1OPRM1 | |
| SCHEMBL17768434 | 0.88 | OPRK1 (0.82) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309725-B2 | Perhydroquinoxaline derivatives, their preparation and use in medicaments | Dr. August Wolff GmbH & Co. KG—Arzneimittel (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20100311761-A1 | PERHYDROQUINOXALINE DERIVATIVES | DR. AUGUST WOLFF GMBH & CO. KG - ARZNEIMITTEL (DE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311761-A1 | PERHYDROQUINOXALINE DERIVATIVES | FH, HOGA1, SDHA | OPRK1 1129/4885OPRM1 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.